Barinthus BiotherapeuticsSTU:2AB 14 Equity-to-Asset is 0.72 as of Mar. 2026, which is 15% below its 10-year median of 0.85. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.95. The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Barinthus Biotherapeutics ranks better than 55.34% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Barinthus Biotherapeutics Equity-to-Asset Related Terms
Barinthus Biotherapeutics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Equity-to-Asset Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Barinthus Biotherapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Equity-to-Asset of 0.72 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Barinthus Biotherapeutics and its competitors. This is 15% below median its historical median of 0.85. According to the industry distribution chart, Barinthus Biotherapeutics ranks #632 out of 1415 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Barinthus Biotherapeutics' Equity-to-Asset too high?
Barinthus Biotherapeutics' current Equity-to-Asset of 0.72 is 15% below median its 10-year median of 0.85. The Biotechnology industry median Equity-to-Asset is 0.68. Barinthus Biotherapeutics' value of 0.72 is 5.9% above this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #632 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Equity-to-Asset compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #632 out of 1415 companies for Equity-to-Asset. This puts Barinthus Biotherapeutics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Barinthus Biotherapeutics' value of 0.72 is 5.9% above this benchmark. While the company's 10-year median is 0.85 vs. the industry median of 0.68, Barinthus Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current Equity-to-Asset of 0.72 is 5.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Equity-to-Asset is 0.72, which is 15% below median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Equity-to-Asset of 0.72. The stock's GF Value™ is €0.95, compared to a current price of €0.54 — trading 43.7% below its estimated fair value. The current Equity-to-Asset is 0.72, which is 15% below median its 10-year median of 0.85 and 5.9% above the Biotechnology industry median of 0.68. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Equity-to-Asset is 0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.54 is trading 43.7% below its estimated GF Value™ of €0.95.
Key valuation signals for STU:2AB:
Equity-to-Asset: 0.72 (15% below median its 10-year median of 0.85)
GF Value™: €0.95 vs. price of €0.54 (43.7% below fair value)
Industry Position: 5.9% above the Biotechnology median (#632 of 1415)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
